Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep 7:10:480.
doi: 10.1186/1471-2407-10-480.

Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma

Ursula M Vogl  1 , Marija Bojic, Wolfgang Lamm, Josa M Frischer, Oskar Pichelmayer, Gero Kramer, Andrea Haitel, Klaus Kitz, Kaan Harmankaya, Christoph C Zielinski, Manuela Schmidinger
Affiliations

Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma

Ursula M Vogl et al. BMC Cancer. .

Abstract

Background: In the era of cytokines, patients with brain metastases (BM) from renal cell carcinoma had a significantly shorter survival than patients without. Targeted agents (TA) have improved the outcome of patients with metastatic renal cell carcinoma (mRCC) however, their impact on patients with BM is less clear. The aim of this analysis was to compare the outcome of patients with and without BM in the era of targeted agents.

Methods: Data from 114 consecutive patients who had access to targeted agent were analyzed for response rates (ORR), progression free survival (PFS) and overall survival (OS). All patients diagnosed with BM underwent local, BM-specific treatment before initiation of medical treatment.

Results: Data of 114 consecutive patients who had access to at least one type of targeted agents were analyzed. Twelve out of 114 renal cell carcinoma (RCC) patients (10.5%) were diagnosed with BM. Systemic treatment consisted of sunitinib, sorafenib, temsirolimus or bevacizumab. The median PFS was 8.7 months (95% CI 5.1 - 12.3) and 11.4 months (95% CI 8.7 - 14.1) for BM-patients and non-BM-patients, respectively (p = 0.232). The median overall survival for patients with and without BM was 13.4 (95% CI 1- 43.9) and 33.3 months (95% CI 18.6 - 47.0) (p = 0.358), respectively. No patient died from cerebral disease progression. ECOG Performance status and the time from primary tumor to metastases (TDM) were independent risk factors for short survival (HR 2.74, p = 0.001; HR: 0.552, p = 0.034).

Conclusions: Although extracerebral metastases determine the outcome of patients with BM, the benefit from targeted agents still appears to be limited when compared to patients without BM.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progression free survival of 114 patients with and without BM. Median PFS: 10.9 months (95%Ci: 8.3-13.5), 11.4 months (95% CI: 8.7-14.1) and 8.7 (95% CI: 5.1-12.3) for the entire population, non-BM-patients and BM-patients, respectively (p = 0.232).
Figure 2
Figure 2
Overall survival of 114 patients with and without BM. Median OS: 33.3 months (95%CI: 19.3-47.2), 33.3 months (95%CI: 18.6-47.9) and 13.4 months (95%CI: 1-43.9) for the entire population, for non-BM and BM patients, respectively (p = 0.358).
See this image and copyright information in PMC

References

    1. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg. 2003;98(2):342–349. doi: 10.3171/jns.2003.98.2.0342. - DOI - PubMed
    1. Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008;113(7):1641–1648. doi: 10.1002/cncr.23769. - DOI - PubMed
    1. Clarke JW, Register S, McGregor JM, Grecula JC, Mayr NA, Wang JZ, Li K, Gupta N, Kendra KL, Olencki TE, Cavaliere R, Sarkar A, Lo SS. Stereotactic Radiosurgery With or Without Whole Brain Radiotherapy for Patients With a Single Radioresistant Brain Metastasis. Am J Clin Oncol. 2009. - PubMed
    1. Marko NF, Angelov L, Toms SA, Suh JH, Chao ST, Vogelbaum MA, Barnett GH, Weil RJ. Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases. Surg Neurol. 2009. - PubMed
    1. Wronski M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology. 1996;47(2):187–193. doi: 10.1016/S0090-4295(99)80413-0. - DOI - PubMed

MeSH terms